BiotechTube
AGC Biologics

AGC Biologics

Copenhagen, Denmark· Est.
agcbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $75M

Overview

AGC Biologics is a global CDMO founded in 2017, specializing in the development and manufacturing of biologics, cell therapies, and gene therapies. It offers end-to-end services across mammalian, microbial, plasmid DNA, mRNA, and viral vector production, supported by proprietary platforms like ProntoLVV™ and BravoAAV™. The company's mission is to partner with biopharma clients to accelerate the delivery of new therapies to patients worldwide.

BiologicsCell TherapyGene Therapy

Technology Platform

Proprietary development and manufacturing platforms for biologics and advanced therapies, including CHEF1™ Expression (mammalian), ProntoLVV™ (lentiviral vectors), BravoAAV™ (adeno-associated viral vectors), and microbial systems.

Funding History

2
Total raised:$75M
Series B$50M
Series A$25M

Opportunities

Explosive growth in cell and gene therapy (CGT) manufacturing demand, coupled with mRNA therapeutic expansion, presents a massive market opportunity.
Its global facility network and proprietary platform programs (e.g., ProntoLVV™) position it to capture clients seeking accelerated, de-risked development paths.
Backing by its parent company, AGC Inc., provides capital for strategic expansion and acquisitions.

Risk Factors

Faces intense competition from large, established CDMOs and specialized rivals, which could pressure pricing and margins.
Operational risks include potential manufacturing failures or contamination events that could damage its reputation and client projects.
The capital-intensive nature of the business and cyclical demand in CGT require careful capacity planning to avoid underutilization.

Competitive Landscape

AGC Biologics competes in a crowded and competitive global CDMO market. Key competitors include large, diversified players like Lonza, Catalent, and Thermo Fisher Scientific (Patheon), as well as pure-play biologics/CDMO firms like Samsung Biologics, Fujifilm Diosynth, and Abzena. In the specialized viral vector and cell therapy space, it competes with companies like Oxford Biomedica, Genezen, and Andelyn Biosciences.

More companies in Biologics / Biosimilars →More companies in Denmark →